Institut de la Vision & 4P-Pharma establish a partnership agreement for the development of an innovative therapy for retinal diseases with the support of the SATT Lutech
Paris, France, 28th January 2021 – 4P-Pharma, a clinical-stage biotechnology company specialized in the sourcing and acceleration of early-stage therapeutic molecules development to the clinic, and the research center, Institut de la Vision (Sorbonne Université, Inserm, CNRS), initiate a partnership for the development of an innovative treatment of dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech. The drug candidate, initially studied by Dr. Valérie Fontaine’s team at the Institut de la Vision, opens a new therapeutic strategy for these diseases.
Read the full press release:Post similaire
16 March 2021
28 January 2021
